PTCT - PTC Therapeutics, Inc.
| Previous Close | 40.37 |
| Open | 40.80 |
| Bid | 42.43 x 900 |
| Ask | 42.59 x 800 |
| Day's Range | 40.80 - 42.77 |
| 52 Week Range | 27.53 - 50.81 |
| Volume | 206,770 |
| Avg. Volume | 770,026 |
| Market Cap | 2.492B |
| Beta (3Y Monthly) | 1.75 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.61 |
| Earnings Date | Aug 5, 2019 - Aug 9, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 50.43 |
- Simply Wall St.•4 days ago
Did You Miss Therapeutics's (NASDAQ:PTCT) Whopping 511% Share Price Gain?
Generally speaking, investors are inspired to be stock pickers by the potential to find the big winners. But when you...
- Insider Monkey•5 days ago
Hedge Funds Have Never Been This Bullish On PTC Therapeutics, Inc. (PTCT)
World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]
- Benzinga•11 days ago
PTC Therapeutics Shares Spike After FDA Approves Drug For Younger Patients
PTC Therapeutics, Inc. (NASDAQ: PTCT ) announced Friday that the Food and Drug Administration approved a label expansion for the drug Emflaza to include younger patients with Duchenne muscular dystrophy ...
- PR Newswire•11 days ago
PTC Therapeutics Receives FDA Approval for the Expansion of the EMFLAZA® (deflazacort) Labeling to Include Patients 2-5 Years of Age
SOUTH PLAINFIELD, N.J., June 7, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced that the U.S. Food and Drug Administration (FDA) approved the company's supplemental New Drug Application (sNDA) for Emflaza® (deflazacort) to expand its labeling to include patients with Duchenne muscular dystrophy who are between 2- and 5-years-old. Emflaza was first approved by the FDA in February 2017 for the treatment of Duchenne in patients 5-years and older.
- PR Newswire•15 days ago
PTC Therapeutics Promotes Emily Hill to Chief Financial Officer
SOUTH PLAINFIELD, N.J. , June 3, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the promotion of Emily Hill to Chief Financial Officer. Ms. Hill joined PTC Therapeutics in November ...
- PR Newswire•18 days ago
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH PLAINFIELD, N.J., May 31, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced that on May 20, 2019 it approved non-statutory stock options to purchase an aggregate of 76,250 shares of its common stock to 15 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires' employment compensation. The inducement grants were approved by PTC's Compensation Committee on May 20, 2019 and are being made as an inducement material to each employee's acceptance of employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).
- PR Newswire•19 days ago
PTC Therapeutics to Participate at Upcoming Investor Conference
SOUTH PLAINFIELD, N.J. , May 30, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the Jefferies Healthcare Conference on Thursday, ...
- PR Newswire•29 days ago
PTC Therapeutics Announces First-Ever Winners of Its PRIORITY Program To Support Research Projects In Rare, Genetic Disorders
SOUTH PLAINFIELD, N.J., May 20, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced the three funding recipients from PRIORITY, an annual program to support outstanding clinical research by the rare genetic disorders community. This year's funding will accelerate innovative research projects to improve Duchenne muscular dystrophy screening in infants and support earlier diagnosis of this progressive, muscle-wasting disease.
- PR Newswire•last month
PTC Therapeutics and MRI Interventions Announce Strategic Investment
SOUTH PLAINFIELD, N.J. and IRVINE, Calif., May 9, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) and MRI Interventions, Inc. (MRIC) today announced a strategic equity investment, with PTC purchasing $4.0 million in shares of MRI common stock. PTC and MRI have also entered into a supply agreement for MRI's neurosurgical devices for PTC's current and future gene therapy programs. MRI is a platform neurosurgery company developing products designed for navigation, ablation, deep brain stimulation, biopsy, aspiration and gene therapy.
- Thomson Reuters StreetEvents•last month
Edited Transcript of PTCT earnings conference call or presentation 2-May-19 8:30pm GMT
Q1 2019 PTC Therapeutics Inc Earnings Call
- PR Newswire•last month
PTC Therapeutics to Participate at Upcoming Investor Conferences
SOUTH PLAINFIELD, N.J. , May 8, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences: Bank of America Merrill ...
- Investor's Business Daily•last month
This Biotech Has A 'Swing Factor' In SMA Drugs And It's Slugging Biogen
PTC Therapeutics and Roche's spinal muscular atrophy treatment showed positive test results early Tuesday — leading shares of rival Ionis Pharmaceuticals and Biogen to slide.
- PR Newswire•last month
Data from Pivotal FIREFISH and SUNFISH Studies Demonstrate Clinical Benefit of Risdiplam in Type 1, 2, & 3 Spinal Muscular Atrophy Patients
Babies with Type 1 SMA from Part 1 of FIREFISH continue to achieve motor milestones including standing 58% of patients experienced an improvement of at least 3 points on MFM32 scale vs. baseline after ...
- Zacks•2 months ago
PTC Therapeutics (PTCT) Reports Q1 Loss, Lags Revenue Estimates
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -22.97% and -24.10%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
PTC Therapeutics: 1Q Earnings Snapshot
On a per-share basis, the South Plainfield, New Jersey-based company said it had a loss of $1.29. Losses, adjusted for non-recurring costs, came to 91 cents per share. The biopharmaceutical company posted ...
- PR Newswire•2 months ago
PTC Therapeutics Reports First Quarter 2019 Financial Results and Provides a Corporate Update
SOUTH PLAINFIELD, N.J., May 2, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced a corporate update and reported financial results for the first quarter ending March 31, 2019. "We believe we are making great strides towards our vision of having many more treatments for patients of rare disorders," said Stuart Peltz, Ph.D., CEO of PTC Therapeutics. "The approval of Translarna expands our footprint in Brazil. Translarna received approval from the Brazilian health regulatory authority (ANVISA) which will allow for expanded market access.
- Insider Monkey•2 months ago
Here is What Hedge Funds Think About PTC Therapeutics, Inc. (PTCT)
"Market conditions are changing. The continued rise in interest rates suggests we are in the early stages of a bond bear market, which could intensify as central banks withdraw liquidity. The receding tide of liquidity will start to reveal more rocks beyond what has been exposed in emerging markets so far, and the value of […]
- PR Newswire•2 months ago
Translarna™ (ataluren) is the First Therapy Approved in Brazil for Duchenne Muscular Dystrophy
SOUTH PLAINFIELD, N.J., April 29, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced that Translarna™ (ataluren) has been granted marketing approval from the Brazilian National Health Surveillance Agency (ANVISA) under rare diseases procedure, for the treatment of ambulatory children five years and older with Duchenne muscular dystrophy caused by a nonsense mutation. Primarily affecting males, Duchenne muscular dystrophy is a rare, irreversible, and fatal genetic disorder that results in progressive muscle weakness from early childhood and leads to premature death in the mid-twenties due to heart and respiratory failure.
- Zacks•2 months ago
Analysts Estimate PTC Therapeutics (PTCT) to Report a Decline in Earnings: What to Look Out for
PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- PR Newswire•2 months ago
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2019 Financial Results
SOUTH PLAINFIELD, N.J. , April 18, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter 2019 financial ...
- Simply Wall St.•2 months ago
Have Insiders Been Selling PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares?
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares. So we'll take a look a...
- CNW Group•3 months ago
Medison to Nominate Six Highly Qualified Directors for Knight Therapeutics' Board to Strengthen Oversight and Drive Value Creation for All Shareholders
PETACH TIKVA, Israel , April 1, 2019 /CNW/ - Medison Biotech (1995) Ltd. ("Medison"), which together with its affiliates owns more than 10.4 million shares or 7.3% of Knight Therapeutics, Inc. (GUD.TO) ("Knight" or the "Company"), today announced that it has nominated six exceptional pharmaceutical industry leaders (the "Nominees") for election to Knight's Board of Directors (the "Board") at the Company's 2019 annual general meeting, in accordance with the Company's Advanced Notice By-Law. Other than Medison's CEO, Meir Jakobsohn, who has served on the Knight Board since 2015, none of the Nominees has any ties to Knight or Medison.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of PTCT earnings conference call or presentation 28-Feb-19 9:30pm GMT
Q4 2018 PTC Therapeutics Inc Earnings Call
- Simply Wall St.•3 months ago
Is PTC Therapeutics, Inc.’s (NASDAQ:PTCT) Balance Sheet Strong Enough To Weather A Storm?
Small and large cap stocks are widely popular for a variety of reasons, however, mid-cap companies such as PTC Therapeutics, Inc. (NASDAQ:PTCT), with a market cap of US$2.1b, often getRead More...
